<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01382719</url>
  </required_header>
  <id_info>
    <org_study_id>PT-141-54</org_study_id>
    <nct_id>NCT01382719</nct_id>
  </id_info>
  <brief_title>Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder</brief_title>
  <official_title>A Placebo-controlled, Randomized, Parallel Group, Dose-finding Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With FSAD (Female Sexual Arousal Disorder) and/or HSDD (Hypoactive Sexual Desire Disorder)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Palatin Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Palatin Technologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed to evaluate the efficacy and safety of 3 fixed dose levels of
      bremelanotide, administered subcutaneously on an as-needed basis under conditions of home
      use, for the treatment of female sexual arousal disorder (FSAD), hypoactive sexual desire
      disorder (HSDD), or mixed FSAD/HSDD in premenopausal women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Efficacy Endpoint is Change From Baseline to End of Study in the Number of Satisfying Sexual Events (SSE)</measure>
    <time_frame>4 - 12 weeks from baseline to end of study (total study duration 20 weeks). Baseline was the 4-week single-blind placebo period.</time_frame>
    <description>The primary efficacy endpoint is change from baseline to end of study in the number of satisfying sexual events (SSEs), computed as the number of events during the last 4 weeks of treatment with FSEP-R Q10 = &quot;Yes&quot; minus the number of baseline events with FSEP-R Q10 = &quot;Yes.&quot; Efficacy analyses were done with the MITT population which consisted of all randomized subjects who took at least 1 dose of double-blind treatment after the 2 in-clinic doses of double-blind medication and who had at least 1 follow-up visit (Visit 10 or later) to ensure that FSEP-R data were reviewed and confirmed by the investigative site.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End-of-Study in Arousal Domain Score From Female Sexual Function Index</measure>
    <time_frame>4-12 weeks from baseline to end of study (total study duration 20 weeks)</time_frame>
    <description>The FSFI is brief self-report questionnaire that measures female sexual function. The change from baseline to end of study in the arousal domain were obtained from the FSFI Q3 through Q6. The score range is 0-5. For each of the 2 time points, the score was computed programmatically using the algorithm described by Rosen [6], resulting in a score from 0 (min) to 6 (max).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction With Arousal as Measured by GAQ Question 1</measure>
    <time_frame>4-12 weeks from baseline to end of study (total study duration 20 weeks)</time_frame>
    <description>This is the change in Baseline to End-of-Study in Satisfaction with Arousal as measured by GAQ Question 1. GAQ (Global Assessment Questions) is a questionnaire that evaluates overall satisfaction level experienced while using the study drug. Question 1 is &quot;Compared to the start of the study (prior to taking the study drug), how would you describe your satisfaction with your arousal while using the study drug?&quot; The score range is 1 (very much worse) to 7 (very much better).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desire Domain From Female Sexual Function Index</measure>
    <time_frame>4-12 weeks from baseline to end of study (total study duration 20 weeks)</time_frame>
    <description>The FSFI is brief self-report questionnaire that measures female sexual function. The change from baseline to end of study in the desire domain were obtained from the FSFI Q1 and Q2. The score range is 1-5. For each of the 2 time points, the score was computed programmatically using the algorithm described by Rosen [6], resulting in a score from 0 (min) to 6 (max).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction With Desire as Measured by GAQ Question 2</measure>
    <time_frame>4-12 weeks from baseline to end of study (total study duration 20 weeks)</time_frame>
    <description>This is the change in Baseline to End-of-Study in Satisfaction with Desire as Measured by GAQ Question 2. GAQ (Global Assessment Questions) is a questionnaire that evaluates overall satisfaction level experienced while using the study drug. Question 2 is &quot;Compared to the start of the study (prior to taking the study drug), how would you describe your satisfaction with your desire while using the study drug?&quot; The score range is 1 (very much worse) to 7 (very much better).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Relationship With Partner as Measured by GAQ Question 4</measure>
    <time_frame>4-12 weeks from baseline to end of study (total study duration 20 weeks)</time_frame>
    <description>This is the change in Baseline to End-of-Study in Quality of Relationship with Partner as Measured by GAQ Question 4. GAQ (Global Assessment Questions) is a questionnaire that evaluates overall satisfaction level experienced while using the study drug. Question 4 is &quot;Compared to the start of the study (prior to taking the study drug), how has taking the study drug changed your relationship with your partner?&quot; The score range is 1 (very much worse) to 7 (very much better).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSDS-DAO Total Score</measure>
    <time_frame>4 - 12 weeks from baseline to end of study (total study duration 20 weeks)</time_frame>
    <description>FSDS-DAO (Female Sexual Distress Scale - Desire/Arousal/Orgasm) is an assessment tool to measure female sexual distress. The change from baseline to end of study in the FSDS-DAO (total score) was measured. There are 15 questions, eg, &quot;How often do you feel: Distressed about your sex life&quot; and the score range was 0 (Never), 1 (Rarely), 2 (Occasionally), 3 (Frequently), 4 (Always). The score for each subject at each time point was computed as the sum of the scores from the 15 questions, resulting in a possible score at each time point between 0 and 60.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">612</enrollment>
  <condition>Female Sexual Arousal Disorder</condition>
  <condition>Hypoactive Sexual Desire Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bremelanotide arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bremelanotide arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Middle dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 1.25 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bremelanotide arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bremelanotide</intervention_name>
    <description>Subjects will administer drug on an as needed basis, prior to anticipated sexual activity.
Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75, 1.25, or 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
Placebo: Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>bremelanotide arm 1</arm_group_label>
    <arm_group_label>bremelanotide arm 2</arm_group_label>
    <arm_group_label>bremelanotide arm 3</arm_group_label>
    <other_name>PT-141</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Female, at least 21 years of age, and premenopausal Previously experienced sexual arousal
        during sexual activity and/or normal level of desire in the past for least 2 years.

        Willing to engage in sexual activities Currently in stable relationship with a partner(male
        or female)for at least 6 months.

        If subject has a male sexual partner, has recorded a score of &quot;not impotent&quot; or &quot;minimally
        impotent&quot; on Single-question Assessment of ED.

        For at least 6 months before Screening, has met diagnostic criteria for FSAD, HSDD, or
        mixed FSAD/HSDD Has a negative serum pregnancy test (hCG) at Screening and, if subject's
        partner is male, has used a medically acceptable form of contraception for the 3 months
        before Screening (Visit 1), and is willing to continue for the duration of the trial and 1
        month following the last dose of trial drug.

        Has a normal pelvic examination. At Screening or documented within 12 months before
        Screening, has:normal Pap test results with or without history of positive HPV, dysplasia,
        or ASCUS that has resolved or been treated;Pap test results positive for ASCUS and negative
        for HPV;Pap test results positive for HPV AND no ASCUS or dysplasia on Pap or condyloma
        present upon examination.

        At Screening and Visit 2, meets all necessary questionnaire scores.

        Exclusion Criteria:

        Medical condition that is unstable or uncontrolled despite current therapy. History of
        unresolved sexual trauma or abuse. Pregnant or nursing. Lifelong anorgasmia, vaginismus,
        sexual pain disorder, sexual aversion disorder, or persistent sexual arousal disorder.

        Female sexual dysfunction caused by untreated endocrine disease. Has or has had any of the
        following: hepatitis C, other infectious hepatitis, infectious blood disorders such as HIV;
        myocardial infarction;stroke.

        Has or has had any of the following within 12 months before Screening:chronic dyspareunia
        not attributable to vaginal dryness; pelvic inflammatory disease; chronic or complicated
        UTI, or an active STD other than herpes and condyloma; cervical dysplasia, including LGSIL
        and HGSIL and/or ASCUS with HPV; significant cervicitis as manifested by mucopurulent
        discharge from the cervix.

        Has had any of the following within 6 months before Screening:≥ 2 outbreaks of genital
        herpes; occurrence/recurrence of clinically significant condyloma;clinically unstable
        angina or clinically unstable arrhythmia;significant CNS diseases;AST or ALT concentrations
        &gt; 3 times the ULN;serum creatinine &gt; 2.5 mg/dL;any other clinically significant abnormal
        laboratory result.

        Has used prohibited medications within the 3 months before Screening:

        Has currently active moderate to severe vaginitis or a clinically significant vaginal
        infection.

        Has one or more significant gynecologic conditions . Is taking or has received treatment
        for psychosis, bipolar disorder, depression, and/or alcohol/substance abuse within 6 months
        before Screening.

        Is currently receiving psychotherapy for the treatment of FSAD and/or HSDD. Has any of the
        following: Uncontrolled hypertension;Systolic BP of ≥ 140 mm Hg at Screening;Diastolic BP
        of ≥ 90 mm Hg at Screening; Treatment for hypertension that has changed in the 3 months
        before Screening.

        Had a hysterectomy with bilateral oophorectomy. Had a hysterectomy without bilateral
        oophorectomy AND meets several other criteria.

        Is taking contraceptives that have affected the menstrual cycle or caused amenorrhea AND
        did not have a normal menstrual cycle before starting the contraceptive medication.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Edelson, MD, FRCPC</last_name>
    <role>Study Director</role>
    <affiliation>Palatin Technologies, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 56</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 26</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 64</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 45</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 39</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 25</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 78</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 16</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 52</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 73</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 80</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 12</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 37</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 40</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 8</name>
      <address>
        <city>Avon</city>
        <state>Connecticut</state>
        <zip>06117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 75</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 33</name>
      <address>
        <city>New London</city>
        <state>Connecticut</state>
        <zip>06320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 32</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 10</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 27</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 66</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 61</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 82</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 55</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 70</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 54</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 63</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 13</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 48</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 57</name>
      <address>
        <city>Zachary</city>
        <state>Louisiana</state>
        <zip>70791</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 9</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 60</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 74</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 35</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 72</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 24</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 18</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 38</name>
      <address>
        <city>Purchase</city>
        <state>New York</state>
        <zip>10577</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 47</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 23</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 69</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 71</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 19</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 30</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 81</name>
      <address>
        <city>Englewood</city>
        <state>Ohio</state>
        <zip>45322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 2</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 42</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 77</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 43</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 58</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 49</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 53</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 59</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 76</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 31</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 17</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 62</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 50</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 36</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <zip>84070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 7</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 68</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 65</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 22</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4</name>
      <address>
        <city>North Vancouver</city>
        <state>British Columbia</state>
        <zip>V7N 2H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 41</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 21</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7R4G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2011</study_first_submitted>
  <study_first_submitted_qc>June 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <results_first_submitted>September 5, 2013</results_first_submitted>
  <results_first_submitted_qc>March 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 14, 2014</results_first_posted>
  <last_update_submitted>December 2, 2014</last_update_submitted>
  <last_update_submitted_qc>December 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FSAD</keyword>
  <keyword>HSDD</keyword>
  <keyword>female sexual dysfunction</keyword>
  <keyword>FSD</keyword>
  <keyword>Female Sexual Arousal Disorder</keyword>
  <keyword>Hypoactive Sexual Desire Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Hypokinesia</mesh_term>
    <mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
    <mesh_term>Sexual Dysfunction, Physiological</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>alpha-MSH</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 1142 subjects were screened at 69 medical sites in the US and Canada, 612 subjects were enrolled, and 488 subjects entered the single-blind placebo treatment period; 397 were randomized, and 394 were dosed with randomized treatment.</recruitment_details>
      <pre_assignment_details>A total of 91 subjects were not randomized due to failing the resting blood pressure criteria (36), withdrawal of consent (24), being lost to follow-up (9), adverse events (5), non-compliance (5), and other reasons (12).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>identical formulation without active ingredient</description>
        </group>
        <group group_id="P2">
          <title>Bremelanotide Arm 1</title>
          <description>low dose 0.75 mg BMT</description>
        </group>
        <group group_id="P3">
          <title>Bremelanotide Arm 2</title>
          <description>middle dose 1.25 mg BMT</description>
        </group>
        <group group_id="P4">
          <title>Bremelanotide Arm 3</title>
          <description>high dose 1.75 mg BMT</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="100"/>
                <participants group_id="P4" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Subjects Not Dosed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="66"/>
                <participants group_id="P4" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>identical formulation without active ingredient</description>
        </group>
        <group group_id="B2">
          <title>Bremelanotide Arm 1</title>
          <description>low dose 0.75 mg BMT</description>
        </group>
        <group group_id="B3">
          <title>Bremelanotide Arm 2</title>
          <description>middle dose 1.25 mg BMT</description>
        </group>
        <group group_id="B4">
          <title>Bremelanotide Arm 3</title>
          <description>high dose 1.75 mg BMT</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="97"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="99"/>
            <count group_id="B4" value="98"/>
            <count group_id="B5" value="394"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.0" spread="7.70"/>
                    <measurement group_id="B2" value="37.6" spread="7.76"/>
                    <measurement group_id="B3" value="35.7" spread="7.22"/>
                    <measurement group_id="B4" value="37.0" spread="7.56"/>
                    <measurement group_id="B5" value="36.9" spread="7.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="98"/>
                    <measurement group_id="B5" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="70"/>
                    <measurement group_id="B5" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Pound</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164.40" spread="42.050"/>
                    <measurement group_id="B2" value="168.17" spread="37.867"/>
                    <measurement group_id="B3" value="173.97" spread="43.229"/>
                    <measurement group_id="B4" value="179.15" spread="45.872"/>
                    <measurement group_id="B5" value="171.41" spread="42.532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.73" spread="6.171"/>
                    <measurement group_id="B2" value="28.47" spread="6.616"/>
                    <measurement group_id="B3" value="29.17" spread="7.096"/>
                    <measurement group_id="B4" value="29.92" spread="7.181"/>
                    <measurement group_id="B5" value="28.82" spread="6.802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Of Childbearing Potential</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Of Childbearing Potential</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgically Sterile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight Quartile</title>
          <units>Pound</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>95 - 143 pounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;143 - 165 pounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;165 - 200.6 pounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;200.6 - 350 pounds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menses Frequency</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Variable cycle length (&lt;7 days different from nor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="79"/>
                    <measurement group_id="B5" value="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Variable cycle length (&gt;7 days different from nor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 or more skipped cycles, and amenorrhea for 60 or</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N.A.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Natural Hair Color</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Red</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Than Red</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="92"/>
                    <measurement group_id="B5" value="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>FSAD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HSDD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed FSAD/HSDD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Oral Contraceptive Use within 30 Days of Visit 1</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="83"/>
                    <measurement group_id="B5" value="341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Efficacy Endpoint is Change From Baseline to End of Study in the Number of Satisfying Sexual Events (SSE)</title>
        <description>The primary efficacy endpoint is change from baseline to end of study in the number of satisfying sexual events (SSEs), computed as the number of events during the last 4 weeks of treatment with FSEP-R Q10 = &quot;Yes&quot; minus the number of baseline events with FSEP-R Q10 = &quot;Yes.&quot; Efficacy analyses were done with the MITT population which consisted of all randomized subjects who took at least 1 dose of double-blind treatment after the 2 in-clinic doses of double-blind medication and who had at least 1 follow-up visit (Visit 10 or later) to ensure that FSEP-R data were reviewed and confirmed by the investigative site.</description>
        <time_frame>4 - 12 weeks from baseline to end of study (total study duration 20 weeks). Baseline was the 4-week single-blind placebo period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>identical formulation without active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Bremelanotide Arm 1</title>
            <description>low dose 0.75 mg BMT</description>
          </group>
          <group group_id="O3">
            <title>Bremelanotide Arm 2</title>
            <description>middle dose 1.25 mg BMT</description>
          </group>
          <group group_id="O4">
            <title>Bremelanotide Arm 3</title>
            <description>high dose 1.75 mg BMT</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Efficacy Endpoint is Change From Baseline to End of Study in the Number of Satisfying Sexual Events (SSE)</title>
          <description>The primary efficacy endpoint is change from baseline to end of study in the number of satisfying sexual events (SSEs), computed as the number of events during the last 4 weeks of treatment with FSEP-R Q10 = &quot;Yes&quot; minus the number of baseline events with FSEP-R Q10 = &quot;Yes.&quot; Efficacy analyses were done with the MITT population which consisted of all randomized subjects who took at least 1 dose of double-blind treatment after the 2 in-clinic doses of double-blind medication and who had at least 1 follow-up visit (Visit 10 or later) to ensure that FSEP-R data were reviewed and confirmed by the investigative site.</description>
          <units>SSEs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="2.29"/>
                    <measurement group_id="O2" value="0.6" spread="3.55"/>
                    <measurement group_id="O3" value="0.7" spread="1.81"/>
                    <measurement group_id="O4" value="0.8" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Van Elteren</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0215</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Van Elteren</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0012</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.0012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End-of-Study in Arousal Domain Score From Female Sexual Function Index</title>
        <description>The FSFI is brief self-report questionnaire that measures female sexual function. The change from baseline to end of study in the arousal domain were obtained from the FSFI Q3 through Q6. The score range is 0-5. For each of the 2 time points, the score was computed programmatically using the algorithm described by Rosen [6], resulting in a score from 0 (min) to 6 (max).</description>
        <time_frame>4-12 weeks from baseline to end of study (total study duration 20 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>identical formulation without active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Bremelanotide Arm 1</title>
            <description>low dose 0.75 mg BMT</description>
          </group>
          <group group_id="O3">
            <title>Bremelanotide Arm 2</title>
            <description>middle dose 1.25 mg BMT</description>
          </group>
          <group group_id="O4">
            <title>Bremelanotide Arm 3</title>
            <description>high dose 1.75 mg BMT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End-of-Study in Arousal Domain Score From Female Sexual Function Index</title>
          <description>The FSFI is brief self-report questionnaire that measures female sexual function. The change from baseline to end of study in the arousal domain were obtained from the FSFI Q3 through Q6. The score range is 0-5. For each of the 2 time points, the score was computed programmatically using the algorithm described by Rosen [6], resulting in a score from 0 (min) to 6 (max).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="1.371"/>
                    <measurement group_id="O2" value="0.35" spread="1.457"/>
                    <measurement group_id="O3" value="0.71" spread="1.112"/>
                    <measurement group_id="O4" value="1.06" spread="1.146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0496</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction With Arousal as Measured by GAQ Question 1</title>
        <description>This is the change in Baseline to End-of-Study in Satisfaction with Arousal as measured by GAQ Question 1. GAQ (Global Assessment Questions) is a questionnaire that evaluates overall satisfaction level experienced while using the study drug. Question 1 is &quot;Compared to the start of the study (prior to taking the study drug), how would you describe your satisfaction with your arousal while using the study drug?&quot; The score range is 1 (very much worse) to 7 (very much better).</description>
        <time_frame>4-12 weeks from baseline to end of study (total study duration 20 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>identical formulation without active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Bremelanotide Arm 1</title>
            <description>low dose 0.75 mg BMT</description>
          </group>
          <group group_id="O3">
            <title>Bremelanotide Arm 2</title>
            <description>middle dose 1.25 mg BMT</description>
          </group>
          <group group_id="O4">
            <title>Bremelanotide Arm 3</title>
            <description>high dose 1.75 mg BMT</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction With Arousal as Measured by GAQ Question 1</title>
          <description>This is the change in Baseline to End-of-Study in Satisfaction with Arousal as measured by GAQ Question 1. GAQ (Global Assessment Questions) is a questionnaire that evaluates overall satisfaction level experienced while using the study drug. Question 1 is &quot;Compared to the start of the study (prior to taking the study drug), how would you describe your satisfaction with your arousal while using the study drug?&quot; The score range is 1 (very much worse) to 7 (very much better).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.37"/>
                    <measurement group_id="O2" value="0.3" spread="1.43"/>
                    <measurement group_id="O3" value="0.5" spread="1.46"/>
                    <measurement group_id="O4" value="0.9" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Van Elteren</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0079</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Desire Domain From Female Sexual Function Index</title>
        <description>The FSFI is brief self-report questionnaire that measures female sexual function. The change from baseline to end of study in the desire domain were obtained from the FSFI Q1 and Q2. The score range is 1-5. For each of the 2 time points, the score was computed programmatically using the algorithm described by Rosen [6], resulting in a score from 0 (min) to 6 (max).</description>
        <time_frame>4-12 weeks from baseline to end of study (total study duration 20 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>identical formulation without active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Bremelanotide Arm 1</title>
            <description>low dose 0.75 mg BMT</description>
          </group>
          <group group_id="O3">
            <title>Bremelanotide Arm 2</title>
            <description>middle dose 1.25 mg BMT</description>
          </group>
          <group group_id="O4">
            <title>Bremelanotide Arm 3</title>
            <description>high dose 1.75 mg BMT</description>
          </group>
        </group_list>
        <measure>
          <title>Desire Domain From Female Sexual Function Index</title>
          <description>The FSFI is brief self-report questionnaire that measures female sexual function. The change from baseline to end of study in the desire domain were obtained from the FSFI Q1 and Q2. The score range is 1-5. For each of the 2 time points, the score was computed programmatically using the algorithm described by Rosen [6], resulting in a score from 0 (min) to 6 (max).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="1.075"/>
                    <measurement group_id="O2" value="0.33" spread="1.093"/>
                    <measurement group_id="O3" value="0.55" spread="0.794"/>
                    <measurement group_id="O4" value="0.95" spread="1.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Van Elteren</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0012</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction With Desire as Measured by GAQ Question 2</title>
        <description>This is the change in Baseline to End-of-Study in Satisfaction with Desire as Measured by GAQ Question 2. GAQ (Global Assessment Questions) is a questionnaire that evaluates overall satisfaction level experienced while using the study drug. Question 2 is &quot;Compared to the start of the study (prior to taking the study drug), how would you describe your satisfaction with your desire while using the study drug?&quot; The score range is 1 (very much worse) to 7 (very much better).</description>
        <time_frame>4-12 weeks from baseline to end of study (total study duration 20 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>identical formulation without active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Bremelanotide Arm 1</title>
            <description>low dose 0.75 mg BMT</description>
          </group>
          <group group_id="O3">
            <title>Bremelanotide Arm 2</title>
            <description>middle dose 1.25 mg BMT</description>
          </group>
          <group group_id="O4">
            <title>Bremelanotide Arm 3</title>
            <description>high dose 1.75 mg BMT</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction With Desire as Measured by GAQ Question 2</title>
          <description>This is the change in Baseline to End-of-Study in Satisfaction with Desire as Measured by GAQ Question 2. GAQ (Global Assessment Questions) is a questionnaire that evaluates overall satisfaction level experienced while using the study drug. Question 2 is &quot;Compared to the start of the study (prior to taking the study drug), how would you describe your satisfaction with your desire while using the study drug?&quot; The score range is 1 (very much worse) to 7 (very much better).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.31"/>
                    <measurement group_id="O2" value="0.3" spread="1.32"/>
                    <measurement group_id="O3" value="0.8" spread="1.44"/>
                    <measurement group_id="O4" value="0.9" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Van Elteren</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0013</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Relationship With Partner as Measured by GAQ Question 4</title>
        <description>This is the change in Baseline to End-of-Study in Quality of Relationship with Partner as Measured by GAQ Question 4. GAQ (Global Assessment Questions) is a questionnaire that evaluates overall satisfaction level experienced while using the study drug. Question 4 is &quot;Compared to the start of the study (prior to taking the study drug), how has taking the study drug changed your relationship with your partner?&quot; The score range is 1 (very much worse) to 7 (very much better).</description>
        <time_frame>4-12 weeks from baseline to end of study (total study duration 20 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>identical formulation without active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Bremelanotide Arm 1</title>
            <description>low dose 0.75 mg BMT</description>
          </group>
          <group group_id="O3">
            <title>Bremelanotide Arm 2</title>
            <description>middle dose 1.25 mg BMT</description>
          </group>
          <group group_id="O4">
            <title>Bremelanotide Arm 3</title>
            <description>high dose 1.75 mg BMT</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Relationship With Partner as Measured by GAQ Question 4</title>
          <description>This is the change in Baseline to End-of-Study in Quality of Relationship with Partner as Measured by GAQ Question 4. GAQ (Global Assessment Questions) is a questionnaire that evaluates overall satisfaction level experienced while using the study drug. Question 4 is &quot;Compared to the start of the study (prior to taking the study drug), how has taking the study drug changed your relationship with your partner?&quot; The score range is 1 (very much worse) to 7 (very much better).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.20"/>
                    <measurement group_id="O2" value="0.3" spread="1.24"/>
                    <measurement group_id="O3" value="0.4" spread="1.22"/>
                    <measurement group_id="O4" value="0.6" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Van Elteren</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.1161</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FSDS–DAO Total Score</title>
        <description>FSDS-DAO (Female Sexual Distress Scale - Desire/Arousal/Orgasm) is an assessment tool to measure female sexual distress. The change from baseline to end of study in the FSDS-DAO (total score) was measured. There are 15 questions, eg, &quot;How often do you feel: Distressed about your sex life&quot; and the score range was 0 (Never), 1 (Rarely), 2 (Occasionally), 3 (Frequently), 4 (Always). The score for each subject at each time point was computed as the sum of the scores from the 15 questions, resulting in a possible score at each time point between 0 and 60.</description>
        <time_frame>4 - 12 weeks from baseline to end of study (total study duration 20 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>identical formulation without active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Bremelanotide Arm 1</title>
            <description>low dose 0.75 mg BMT</description>
          </group>
          <group group_id="O3">
            <title>Bremelanotide Arm 2</title>
            <description>middle dose 1.25 mg BMT</description>
          </group>
          <group group_id="O4">
            <title>Bremelanotide Arm 3</title>
            <description>high dose 1.75 mg BMT</description>
          </group>
        </group_list>
        <measure>
          <title>FSDS–DAO Total Score</title>
          <description>FSDS-DAO (Female Sexual Distress Scale - Desire/Arousal/Orgasm) is an assessment tool to measure female sexual distress. The change from baseline to end of study in the FSDS-DAO (total score) was measured. There are 15 questions, eg, &quot;How often do you feel: Distressed about your sex life&quot; and the score range was 0 (Never), 1 (Rarely), 2 (Occasionally), 3 (Frequently), 4 (Always). The score for each subject at each time point was computed as the sum of the scores from the 15 questions, resulting in a possible score at each time point between 0 and 60.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" spread="13.57"/>
                    <measurement group_id="O2" value="-7.4" spread="13.47"/>
                    <measurement group_id="O3" value="-9.2" spread="10.79"/>
                    <measurement group_id="O4" value="-13.1" spread="12.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.0133</param_value>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>identical formulation without active ingredient</description>
        </group>
        <group group_id="E2">
          <title>Bremelanotide Arm 1</title>
          <description>low dose 0.75 mg BMT</description>
        </group>
        <group group_id="E3">
          <title>Bremelanotide Arm 2</title>
          <description>middle dose 1.25 mg BMT</description>
        </group>
        <group group_id="E4">
          <title>Bremelanotide Arm 3</title>
          <description>high dose 1.75 mg BMT</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Escherichia bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 14</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="67" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="34" subjects_affected="18" subjects_at_risk="100"/>
                <counts group_id="E3" events="63" subjects_affected="22" subjects_at_risk="99"/>
                <counts group_id="E4" events="51" subjects_affected="24" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E4" events="11" subjects_affected="6" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Abdominal pain/discomfort, lower/upper abdominal pain, dyspepsia (1% each)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E3" events="10" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" events="26" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Injection/vessel puncture site hematoma (1% each)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Feeling hot/jittery, inj site reac/hemorrhage/rash, pain, chest pain (1% each)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E4" events="12" subjects_affected="7" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity, seasonal allergy (1% each)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Fungal infect, gastroenter/bronchitis, vulvo/vaginitis, follicul/pharyngitis, tooth abcess (1% each)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion, fall, joint sprain, procedural dizziness/pain, thermal pain (1% each)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>CPK/glu/lipase/chol/BP/triglycerides increased, iron decreased, MCV abnormal (1% each)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain/myalgia, arthralgia, muscle spasms, flank pain (1% each)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E4" events="13" subjects_affected="6" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Melanocytic nevus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E3" events="14" subjects_affected="10" subjects_at_risk="99"/>
                <counts group_id="E4" events="18" subjects_affected="15" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E4" events="23" subjects_affected="7" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E4" events="20" subjects_affected="3" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Migraine, sciatica, sinus headache (1% each)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia, libido increased, restlessness (1% each)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" events="22" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vag hemorrh/discharge, breast tend/mass, metrorrhagia, menstru irreg, genit discomfort/order (1% ea)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Cough, nasal/sinus congestion (1% each)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne, pruritis, dermatitis contact, erythema, rash, urticaria (1% each)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="36" subjects_affected="17" subjects_at_risk="100"/>
                <counts group_id="E3" events="46" subjects_affected="15" subjects_at_risk="99"/>
                <counts group_id="E4" events="34" subjects_affected="17" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Hematoma, hot flush (1% each)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey Edelson, MD, FRCPC</name_or_title>
      <organization>Palatin Technologies, Inc.</organization>
      <phone>(609) 495-2200</phone>
      <email>jedelson@palatin.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

